comprehensive -WSS

comprehensive

author：focus 2025-09-06 01:58:43 - browse：179

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： iTeos Therapeutics debuts first data on TIGIT

focus

leisure time

WSS

FDA struggles to regulate food additives, sometimes for decades

Studies point to risks of excluding people with obesity from drug trials

Focused ultrasound for uterine fibroids: an uphill battle

STAT Readout Newsletter: Today's biggest biotech updates

Do more moles mean more problems? Not so, says new study

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Scientists successfully use ultrasound imaging to map brain activity

How to save PrEP access — and even expand it

The explosion of genetic testing requires a new approach

Affirmative action in medical school literally saved lives

The explosion of genetic testing requires a new approach

Heart attack and stroke risk calculators need revising

CEOs share strategies for surviving biotech slump

Drug repurposing or repositioning? The language matters

Focused ultrasound for uterine fibroids: an uphill battle

hotspot

Report: NIH

The EU Joint Clinical Assessment needs to live up to its promise

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Hospital price transparency does save money, advocate argues

Hospital price transparency does save money, advocate argues

First Opinion Podcast: Long Covid needs a new approach

hotspot

focus

leisure time

hotspot